IPO round-up: K2M lists on Nasdaq; skin Dx firm aims for $25m IPO; Siemens to spin out audiology unit
This article was originally published in Clinica
Executive Summary
Spinal device company K2M has moved ahead with its initial public offering on the Nasdaq, joining the growing wave of medtech floats this year. The Leesburg, Virgina-based firm saw its stock open at $15 per share on 8 May – over 5.4 million shares were traded through the day, dipping to a low of $14.51 and hitting a high of $15.23, before settling back and closing at $15. The pricing is a tad lower than what the company had anticipated. At the end of April, K2M had said in a SEC filing that it planned to sell 8.8 million shares at $16-18 each. K2M, listed under the ticker symbol KTWO, develops complex and minimally invasive technologies to treat difficult and challenging spinal pathologies.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.